43 citations,
December 2020 in “PLOS Genetics” New method finds genetic links between Type 2 Diabetes and Prostate Cancer not seen before.
36 citations,
January 2003 in “Molecular and Cellular Biochemistry” 25 citations,
December 2008 in “The Journal of Urology” Short-term finasteride treatment may lower some cell death factors in prostate cancer cells.
19 citations,
August 2014 in “Journal of Ethnopharmacology” The study created a test that found hormonal and toxic effects in plant and fungal extracts using prostate cancer cells.
18 citations,
January 1998 in “Endocrine” RU58841, a nonsteroidal anti-androgen, showed potential as a topical treatment for hair loss, increasing hair density, thickness, and length without systemic side effects in Stumptailed Macaques.
12 citations,
February 1975 in “Journal of Steroid Biochemistry” 8 citations,
July 2021 in “F1000Research” Plant-based compounds might be a promising alternative for prostate cancer treatment with fewer side effects.
4 citations,
November 2017 in “Cancer Causes & Control” Men who start balding at age 20 may have a higher chance of getting aggressive prostate cancer.
4 citations,
June 1998 in “The Journal of Clinical Endocrinology & Metabolism” KGF and its receptor are found in enlarged prostate tissue and KGF strongly increases cell growth.
1 citations,
January 2021 in “Research Square (Research Square)” Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
September 2011 in “Urology” The IPP index is linked to storage symptoms and leftover urine, and may help manage urinary tract symptoms.
September 2009 in “European Urology Supplements” IGRT resulted in lower acute toxicity for stage III prostate cancer patients.
September 2009 in “European Urology Supplements” Cone beam computed tomography can allow for smaller safety margins around the target area in prostate cancer radiation treatment if used for ongoing treatment checks.
6 citations,
January 2016 in “International Journal of Trichology” The conclusion is that more hair loss (androgenetic alopecia) is linked to larger prostate size, suggesting hair loss could be an early sign of benign prostatic hyperplasia.
5 citations,
September 1998 in “Medical hypotheses” Hormone therapy might be a proactive alternative to watchful waiting for early-stage prostate cancer, potentially improving survival without aggressive treatment downsides.
3 citations,
March 2016 in “Phytotherapy Research” The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
2 citations,
April 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” The new method found new shared genetic areas linked to both Type 2 Diabetes and Prostate Cancer.
August 2019 in “The Journal of Urology” Treatment with 5α-reductase inhibitors is linked to a delay in prostate cancer diagnosis and may affect survival rates.
71 citations,
April 2020 in “Journal of Cosmetic Dermatology” Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.
September 2022 in “Frontiers in Immunology” Anti-androgen therapy may boost immunity but increases injection site pain in vaccinated patients.
218 citations,
December 2011 in “Advances in Urology” The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.
110 citations,
April 2002 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dihydrotestosterone gel improved well-being and sexual function in older men without negatively affecting prostate health.
88 citations,
February 2008 in “Journal of Medicinal Chemistry” Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.
72 citations,
October 1998 in “Baillière's clinical endocrinology and metabolism” Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.
54 citations,
November 2001 in “Urology” The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.
51 citations,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
51 citations,
June 1970 in “British journal of dermatology/British journal of dermatology, Supplement” Antiandrogens may help treat conditions like excessive hair growth, prostate tumors, male baldness, and acne by blocking male hormone effects.
42 citations,
May 2007 in “Endocrinology and metabolism/American journal of physiology: endocrinology and metabolism” Testosterone can build muscle and bone without enlarging the prostate when a specific enzyme is blocked.
41 citations,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.